Last reviewed · How we verify
NCT03043287
Voiding Efficiency, a Predictor of Clean Intermittent Catheterization (CIC)
trial testing onabotulinumtoxinA in Urinary Bladder, Overactive in 420 participants. Completed in 30 September 2019.
9 September 2019
Quick facts
| Lead sponsor | Allergan |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 420 |
| Start date | 12 May 2017 |
| Primary completion | 9 September 2019 |
| Estimated completion | 30 September 2019 |
| Sites | 3 locations across United States |
Drugs / interventions tested
- onabotulinumtoxinA (ONABOTULINUMTOXINA) — full drug profile →
Conditions studied
- Urinary Bladder, Overactive — all drugs for Urinary Bladder, Overactive →
Sponsor
Allergan — full company profile →
Who can join
18 and older, any sex, with Urinary Bladder, Overactive. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a retrospective chart review of patients treated with onabotulinumtoxinA (BOTOX®) for idiopathic overactive bladder (OAB) and will determine voiding efficiency (VE) cutoff ratios that predict post-procedure urinary retention requiring catheterization.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03043287
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of onabotulinumtoxinA
Trials testing the same drug.
- NCT03827122 — Botulinum Toxin A Injectable Solution in the Management of Bruxism: A Clinical Trial Study · Phase 2 · unknown
- NCT03373162 — Functional Effects of Botox on the Brain Using MRS and fMRI · Phase 4 · completed
- NCT03052764 — Evaluation of an Alternative Injection Paradigm for OnabotulinumtoxinA (BOTOX®) in the Treatment of Overactive Bladder i · Phase 4 · completed
- NCT02191579 — Efficacy and Safety Study of BOTOX® Compared to Topiramate for the Prevention of Chronic Migraine in Adults · Phase 4 · completed
- NCT02176356 — Patient Satisfaction Study of Combined Facial Treatment With BOTOX® Cosmetic, JUVÉDERM® and LATISSE® (HARMONY Study) · Phase 4 · completed
Other recruiting trials for Urinary Bladder, Overactive
Currently open trials in the same condition.
- NCT06201013 — Vitamin D Treat-to-Target Strategy for Children With Overactive Bladder-Wet · NA · recruiting
- NCT07366918 — Comparison of the Efficacy of Perineal and Intravaginal Electrical Stimulation in Women With Idiopathic Overactive Bladd · NA · recruiting
- NCT06933407 — Elastographic Assessment of Suburethral Tissue in Continent and Incontinent Women · recruiting
- NCT05715268 — Wearables for the Bladder: an In-home Treatment Feasibility Pilot Study · NA · active not recruiting
- NCT06479720 — Efficacy of Solifenacin or Mirabegron With Local Estrogen Versus Combination Pharmacotherapy for Overactive Bladder · Phase 4 · recruiting
Other Allergan trials
Trials by the same sponsor.
- NCT04609020 — Study to Evaluate Subject Satisfaction With Facial Appearance and Impact of Combined Facial Treatment · Phase 4 · completed
- NCT05452070 — A Study to Assess Adverse Events and Change in Disease Activity of HArmonyCa Lidocaine Injectable Gel for Mid Face Soft · Phase 3 · completed
- NCT05393089 — Study of AGN-190584 Eye Drops to Assess Safety and Efficacy in Participants Aged 40-80 Years With Pseudophakic Presbyopi · Phase 2 · withdrawn
- NCT05152576 — A Study To Assess the Adverse Effects and Change in Condition of OnabotulinumtoxinA X Injection in Adult Participants Wi · Phase 2 · completed
- NCT05088980 — Study to Assess Effectiveness and Adverse Events of JUVEDERM VOLBELLA With Lidocaine Injection in Correcting Infraorbita · Phase 3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03043287 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Allergan
- Last refreshed: 5 February 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03043287.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing